Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

By LabMedica International staff writers
Posted on 16 Nov 2026

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories. Expanding access to decentralized testing requires technologies that balance speed, simplicity, and diagnostic performance. A new molecular diagnostics platform demonstrates sample-to-answer detection in under 10 minutes using CRISPR technology without target amplification.

VedaBio presented proof-of-concept data for its integrated, target amplification-free CRISPR-based molecular diagnostics platform at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle, Washington. The technology is being developed to address five key priorities in molecular testing: speed, simplicity, breadth, accuracy, and cost-effectiveness. The findings were presented in a technical poster titled “Target-Amplification-Free CRISPR-Cas Nucleic Acid Detection with OR-Logic Multiplexing Enables Clinically Relevant, Rapid Point-of-Care Testing.”


Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

The integrated prototype was evaluated in a proof-of-concept study using a five-result respiratory panel, demonstrating rapid multiplex molecular detection through a workflow that included automated nucleic acid extraction. Unlike conventional molecular methods, the CRISPR-based technology detects targets without requiring amplification, potentially reducing testing time and procedural complexity.

The demonstration achieved sample-to-answer results in under 10 minutes, highlighting the platform’s potential to combine rapid multiplex detection with a streamlined workflow. VedaBio is developing the technology for decentralized and point-of-need testing, including urgent care and other settings where timely molecular diagnostics could support clinical decision-making.

“Molecular diagnostics should not have to come with trade-offs between speed, complexity and performance. Our goal is to challenge those limitations and bring the benefits of molecular testing closer to patients. These findings demonstrate exciting progress toward that vision and underscore the potential of our CRISPR-based approach to help redefine what is possible at the point of care,” said Brett Robb, PhD, Chief Scientific Officer of VedaBio.

Related Links
VedaBio


Latest Molecular Diagnostics News